Morning Overview on MSN
A new pancreatic-cancer drug nearly doubled survival and cut the risk of death by 60%
Patients with previously treated metastatic pancreatic cancer lived nearly twice as long when given daraxonrasib compared ...
The final set of your workout is about to get a lot more interesting.
TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results